CBL0137

TargetMol
Product Code: TAR-T4126
Supplier: TargetMol
CodeSizePrice
TAR-T4126-1mg1mg£137.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4126-1mL1 mL * 10 mM (in DMSO)£373.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4126-5mg5mg£373.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4126-10mg10mg£515.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4126-25mg25mg£767.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4126-50mg50mg£1,026.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4126-100mg100mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
CBL0137, a metabolically stable curaxin, activates p53 (EC50: 0.37 μM) and inhibits NF-κB (EC50: 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates the efficacy of gemcitabine in preClinicalal models of pancreatic cancer.
CAS:
1197996-80-7
Formula:
C21H24N2O2
Molecular Weight:
336.435
Pathway:
Apoptosis; NF-κb
Purity:
0.98
SMILES:
CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O
Target:
NF-κB; p53

References

Burkhart, C. et al. Curaxin CBL20137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preClinicalal models of pancreatic cancer. Oncotarget 5(22), 11038-11053 (2014). Gasparian, AV. et al. Curaxins: Anticancer compounds that simultaneously suppress NF-?B and activate p53 by targeting FACT. Sci.Transl.Med. 3(95), (2011).